| Size | Price | Stock | Qty |
|---|---|---|---|
| 1mg |
|
||
| 5mg |
|
||
| 100mg | |||
| Other Sizes |
| Targets |
CEA is a cell surface glycoprotein involved in cell adhesion. It binds to itself and other proteins, mediating homophilic and heterophilic interactions. It is not a drug target but a biomarker. Anti-CEA antibodies target CEA for diagnostic and therapeutic purposes.
|
|---|---|
| ln Vitro |
CEA is a tumor marker used in the diagnosis of lung cancer. application of CEA as a predictive and prognostic marker. Normally produced during fetal development, CEA is a glycoprotein involved in cell adhesion that stops producing before birth. The specialized sialyfucosylated glycoform of CEA, a glycosylphosphatidylinositol (GPI) cell surface-anchored glycoprotein, functions as an L- and E-selectin ligand for colon cancer and may be essential for the metastasis and spread of colon cancer cells [1].
In vitro, CEA is used as an antigen in immunoassays for the detection of anti-CEA antibodies. It is also used in cell-based assays to study cancer cell adhesion and migration. CEA-expressing cells are used to evaluate the efficacy of anti-CEA therapies. |
| ln Vivo |
In vivo, CEA is used as a target for imaging and therapy. Radiolabeled anti-CEA antibodies are used for PET/SPECT imaging of CEA-expressing tumors. Anti-CEA antibodies and antibody-drug conjugates are being developed for the treatment of CEA-positive cancers.
|
| Enzyme Assay |
CEA levels are measured in serum or plasma using immunoassays (ELISA, chemiluminescence). The assay uses anti-CEA antibodies to capture and detect CEA. The concentration of CEA is determined from a standard curve.
|
| Cell Assay |
CEA-expressing cancer cells (e.g., LS174T, SW620) are cultured. Cell surface CEA expression is confirmed by flow cytometry. The cells are used in binding assays with anti-CEA antibodies or in cytotoxicity assays with anti-CEA antibody-drug conjugates.
|
| Animal Protocol |
Animal models use mice bearing CEA-expressing xenograft tumors. Radiolabeled anti-CEA antibodies are administered for imaging. Anti-CEA therapies (antibodies, ADCs, CAR-T cells) are evaluated by measuring tumor growth and survival.
|
| ADME/Pharmacokinetics |
CEA is a large glycoprotein (MW ~180-200 kDa). It is shed from tumor cells into the bloodstream. Its half-life in circulation is approximately 2-6 days. It is cleared by the liver and kidneys.
|
| Toxicity/Toxicokinetics |
CEA is an endogenous protein. No toxicity is associated with CEA itself. Anti-CEA therapies may have toxicity related to the therapeutic agent (e.g., antibody, ADC).
|
| References | |
| Additional Infomation |
A glycoprotein secreted onto the luminal surface of the gastrointestinal epithelium. It is present in feces and pancreatic and biliary secretions and is used to monitor response to colon cancer treatment.
CEA is a tumor marker used in cancer diagnostics. It is not a therapeutic drug. Anti-CEA antibodies and related therapies are in development for cancer treatment. CEA is also known as CD66e. |
| Molecular Formula |
C43H69N11O14
|
|---|---|
| Molecular Weight |
964.0733
|
| Exact Mass |
963.502
|
| CAS # |
168635-85-6
|
| PubChem CID |
10306739
|
| Appearance |
White to off-white solid powder
|
| LogP |
-4.3
|
| Hydrogen Bond Donor Count |
14
|
| Hydrogen Bond Acceptor Count |
15
|
| Rotatable Bond Count |
30
|
| Heavy Atom Count |
68
|
| Complexity |
1770
|
| Defined Atom Stereocenter Count |
8
|
| SMILES |
O=C([C@]([H])(C([H])([H])C([H])(C([H])([H])[H])C([H])([H])[H])N([H])C([C@]([H])(C([H])([H])C(N([H])[H])=O)N([H])C([C@]([H])(C([H])([H])[H])N([H])C(C([H])([H])N([H])C([C@]([H])(C([H])([H])O[H])N([H])C([C@]([H])(C([H])([H])C([H])(C([H])([H])[H])C([H])([H])[H])N([H])C([C@]([H])(C([H])([H])C1C([H])=C([H])C(=C([H])C=1[H])O[H])N([H])[H])=O)=O)=O)=O)=O)=O)N([H])[C@@]([H])(C([H])([H])C(N([H])[H])=O)C(N([H])[C@]([H])(C(=O)O[H])C([H])([H])C([H])(C([H])([H])[H])C([H])([H])[H])=O
|
| InChi Key |
JHESAKNQFPFWLN-UOGODTEOSA-N
|
| InChi Code |
InChI=1S/C43H69N11O14/c1-20(2)12-27(50-37(61)26(44)15-24-8-10-25(56)11-9-24)40(64)54-32(19-55)38(62)47-18-35(59)48-23(7)36(60)49-29(16-33(45)57)41(65)51-28(13-21(3)4)39(63)52-30(17-34(46)58)42(66)53-31(43(67)68)14-22(5)6/h8-11,20-23,26-32,55-56H,12-19,44H2,1-7H3,(H2,45,57)(H2,46,58)(H,47,62)(H,48,59)(H,49,60)(H,50,61)(H,51,65)(H,52,63)(H,53,66)(H,54,64)(H,67,68)/t23-,26-,27-,28-,29-,30-,31-,32-/m0/s1
|
| Chemical Name |
(2S)-2-[[(2S)-4-amino-2-[[(2S)-2-[[(2S)-4-amino-2-[[(2S)-2-[[2-[[(2S)-2-[[(2S)-2-[[(2S)-2-amino-3-(4-hydroxyphenyl)propanoyl]amino]-4-methylpentanoyl]amino]-3-hydroxypropanoyl]amino]acetyl]amino]propanoyl]amino]-4-oxobutanoyl]amino]-4-methylpentanoyl]amino]-4-oxobutanoyl]amino]-4-methylpentanoic acid
|
| HS Tariff Code |
2934.99.9001
|
| Storage |
Powder -20°C 3 years 4°C 2 years In solvent -80°C 6 months -20°C 1 month Note: Please store this product in a sealed and protected environment (e.g. under nitrogen), avoid exposure to moisture and light. |
| Shipping Condition |
Room temperature (This product is stable at ambient temperature for a few days during ordinary shipping and time spent in Customs)
|
| Solubility (In Vitro) |
H2O : ~12.5 mg/mL (~12.97 mM)
|
|---|---|
| Solubility (In Vivo) |
Note: Listed below are some common formulations that may be used to formulate products with low water solubility (e.g. < 1 mg/mL), you may test these formulations using a minute amount of products to avoid loss of samples.
Injection Formulations
Injection Formulation 1: DMSO : Tween 80： Saline = 10 : 5 : 85 (i.e. 100 μL DMSO stock solution → 50 μL Tween 80 → 850 μL Saline)(e.g. IP/IV/IM/SC) *Preparation of saline: Dissolve 0.9 g of sodium chloride in 100 mL ddH ₂ O to obtain a clear solution. Injection Formulation 2: DMSO : PEG300 ：Tween 80 : Saline = 10 : 40 : 5 : 45 (i.e. 100 μL DMSO → 400 μLPEG300 → 50 μL Tween 80 → 450 μL Saline) Injection Formulation 3: DMSO : Corn oil = 10 : 90 (i.e. 100 μL DMSO → 900 μL Corn oil) Example: Take the Injection Formulation 3 (DMSO : Corn oil = 10 : 90) as an example, if 1 mL of 2.5 mg/mL working solution is to be prepared, you can take 100 μL 25 mg/mL DMSO stock solution and add to 900 μL corn oil, mix well to obtain a clear or suspension solution (2.5 mg/mL, ready for use in animals). View More
Injection Formulation 4: DMSO : 20% SBE-β-CD in saline = 10 : 90 [i.e. 100 μL DMSO → 900 μL (20% SBE-β-CD in saline)] Oral Formulations
Oral Formulation 1: Suspend in 0.5% CMC Na (carboxymethylcellulose sodium) Oral Formulation 2: Suspend in 0.5% Carboxymethyl cellulose Example: Take the Oral Formulation 1 (Suspend in 0.5% CMC Na) as an example, if 100 mL of 2.5 mg/mL working solution is to be prepared, you can first prepare 0.5% CMC Na solution by measuring 0.5 g CMC Na and dissolve it in 100 mL ddH2O to obtain a clear solution; then add 250 mg of the product to 100 mL 0.5% CMC Na solution, to make the suspension solution (2.5 mg/mL, ready for use in animals). View More
Oral Formulation 3: Dissolved in PEG400 (Please use freshly prepared in vivo formulations for optimal results.) |
| Preparing Stock Solutions | 1 mg | 5 mg | 10 mg | |
| 1 mM | 1.0373 mL | 5.1863 mL | 10.3727 mL | |
| 5 mM | 0.2075 mL | 1.0373 mL | 2.0745 mL | |
| 10 mM | 0.1037 mL | 0.5186 mL | 1.0373 mL |
*Note: Please select an appropriate solvent for the preparation of stock solution based on your experiment needs. For most products, DMSO can be used for preparing stock solutions (e.g. 5 mM, 10 mM, or 20 mM concentration); some products with high aqueous solubility may be dissolved in water directly. Solubility information is available at the above Solubility Data section. Once the stock solution is prepared, aliquot it to routine usage volumes and store at -20°C or -80°C. Avoid repeated freeze and thaw cycles.
Calculation results
Working concentration： mg/mL；
Method for preparing DMSO stock solution： mg drug pre-dissolved in μL DMSO (stock solution concentration mg/mL). Please contact us first if the concentration exceeds the DMSO solubility of the batch of drug.
Method for preparing in vivo formulation:：Take μL DMSO stock solution, next add μL PEG300, mix and clarify, next addμL Tween 80, mix and clarify, next add μL ddH2O，mix and clarify.
(1) Please be sure that the solution is clear before the addition of next solvent. Dissolution methods like vortex, ultrasound or warming and heat may be used to aid dissolving.
(2) Be sure to add the solvent(s) in order.
Link: https://clinicaltrials.gov/ct2/show/NCT00057915
Conditions:Unspecified Adult Solid Tumor, Protocol SpecificLink: https://clinicaltrials.gov/ct2/show/NCT00003434
Conditions:Pancreatic CancerProducts are for research use only; We do not sell to patients
Copyright 2020 InvivoChem LLC | All Rights Reserved
